Treatment for Fabry disease fast-tracked

I reported previously (Jan 2015) on the promising trials for the Fabry disease treatment PRX-102 from Israel’s Protalix. PRX-102 is currently in Phase III trials and has just been granted fast-track status by the US FDA. Fabry disease damages the kidneys and heart and has no cure.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *